As in 2020, CRISPR still doesn't have an approved product -- but that could change soon. The stock has been volatile, providing investors with potential for both big gains and losses. But now that the ...

LabRoots invites you to the 3rd Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory. The company ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

New Early Access Express License provides streamlined, affordable access to foundational CRISPR/Cas9 intellectual property to ...